Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) announced its quarterly earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04, FiscalAI reports. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 47.18%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.16 million.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $3.82 on Wednesday. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $4.47 and a 200-day moving average of $3.59. Perspective Therapeutics has a 1-year low of $1.96 and a 1-year high of $6.16.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CATX. B. Riley Financial upped their target price on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th. HC Wainwright increased their price objective on Perspective Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Piper Sandler initiated coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price objective for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $12.63.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $28,000. Russell Investments Group Ltd. lifted its position in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the last quarter. nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the fourth quarter valued at about $31,000. Engineers Gate Manager LP acquired a new stake in Perspective Therapeutics in the fourth quarter valued at about $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Perspective Therapeutics during the fourth quarter worth about $42,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.